Arca
Skip to content
Tools
Tools

Mycoses

Drug research and approvals for mycoses: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 696 studies of mycoses are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 3 authorised medicines for it.

  • Recruiting worldwide: 696
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 0
  • EU medicines: 3

Recruiting now

Newest start dates first, of 696 recruiting on ClinicalTrials.gov ↗

Drug pipeline

8 approved, 8 in phase 3, 5 in phase 2, 9 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Posaconazole, Voriconazole, Itraconazole, Amphotericin b, Caspofungin, Clotrimazole, Triamcinolone acetonide, Miconazole

Micafungin
Phase 3 1,3-beta-glucan synthase inhibitor
Fluconazole
Phase 3 Cytochrome P450 51 inhibitor
Metronidazole
Phase 3 DNA inhibitor
Rifabutin
Phase 3 Bacterial DNA-directed RNA polymerase inhibitor
Azithromycin
Phase 3 Bacterial 70S ribosome inhibitor
Isavuconazonium
Phase 3 Lanosterol 14-alpha demethylase inhibitor
Polihexanide
Phase 3 Cell membrane disrupting agent
Fosmanogepix
Phase 2 GPI-anchored wall transfer protein 1 inhibitor
Olorofim
Phase 2 Dihydroorotate dehydrogenase (quinone), mitochondrial inhibitor
Natamycin
Phase 2 Ergosterol sequestering agent
Rolusafine
Phase 2
Ibrexafungerp
Phase 1 1,3-beta-glucan synthase inhibitor
Rifampin
Phase 1 Bacterial DNA-directed RNA polymerase inhibitor
Anidulafungin
Phase 1 1,3-beta-glucan synthase inhibitor
Terbinafine
Phase 1 Squalene monooxygenase inhibitor
Ravuconazole
Phase 1 Cytochrome P450 51 inhibitor
Rezafungin
Phase 1 Candida inhibitor
Dextrose
Phase 1
Manogepix
Phase 1
Oteseconazole
Phase 1 Lanosterol 14-alpha demethylase inhibitor

How its trials ended

588 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 147 whose ending is known, 40% met their primary endpoint, 3% missed it and 56% stopped early.

  • Completed, result not reported27947%
  • Ongoing9616%
  • Status unknown6611%
  • Met its primary endpoint5910%
  • Stopped: other or unclear376%
  • Stopped: enrollment or feasibility254%
  • Stopped: sponsor or business decision122%
  • Missed its primary endpoint51%
  • Stopped: funding51%
  • Stopped: lack of efficacy41%

Medicines authorised in the EU

Newest first
Jul 25, 2019Posaconazole AccordPosaconazole · genericAccord Healthcare S.L.U.EMA ↗
Jul 25, 2019Posaconazole AHCLPosaconazole · genericAccord Healthcare S.L.U.EMA ↗
May 27, 2015Voriconazole Hikma (previously Voriconazole Hospira)Voriconazole · genericHikma Farmaceutica (Portugal) S.A.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.